Pre-Operative Left Ventricular Torsion, QRS Width/CRT, and Post-Mitral Surgery Outcomes in Patients With Nonischemic, Chronic, Severe Secondary Mitral Regurgitation

Yuichi Notomi, MD,a Tadashi Isomura, MD,b Shunichi Kanai, RDQS,a Masami Maeda, RN,b Joji Hoshino, MD,b Taichi Kondo, MD,a Yasuhisa Fukada, MD,b Koji Furukawa, MDb

VISUAL ABSTRACT

HIGHLIGHTS
- Determining which patients with NICSMR will benefit from MS is a clinical dilemma.
- LV torsion (which is a shear strain, not volume strain such as ejection fraction and originates in LV myocardial architectures) may reveal the myopathic conditions and reflect intra-LV electrical conduction.
- The LV torsional profile predicted post-MS outcomes in NICSMR patients with a narrow QRS but not in those with a wide QRS.
- The findings may help to resolve the clinical dilemma and identify appropriate candidates for mitral surgery (and other resources) in patients with NICSMR.

From the aDivision of Cardiovascular Imaging, Department of Cardiology, The Hayama Heart Center, Kanagawa, Japan; and the bDepartment of Cardiovascular Surgery, The Hayama Heart Center, Kanagawa, Japan. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received March 7, 2016; revised manuscript received April 25, 2016, accepted April 26, 2016.
The selection of appropriate candidates for mitral surgery among symptomatic patients with nonischemic, chronic, secondary severe mitral regurgitation (NICSMR) remains a clinical challenge. We studied 50 consecutive symptomatic NICSMR patients for a median follow-up of 2.5 years after mitral surgery and concluded that the pre-operative 2-dimensional speckle tracking echocardiography-derived left ventricular torsional profile and QRS width/cardiac resynchronization therapy are potentially important prognostic indicators for post-surgery survival and reverse remodeling. (J Am Coll Cardiol Basic Trans Science 2016;1:193–202) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

SUMMARY

The selection of appropriate candidates for mitral surgery among symptomatic patients with nonischemic, chronic, secondary severe mitral regurgitation (NICSMR) remains a clinical challenge. We studied 50 consecutive symptomatic NICSMR patients for a median follow-up of 2.5 years after mitral surgery and concluded that the pre-operative 2-dimensional speckle tracking echocardiography-derived left ventricular torsional profile and QRS width/cardiac resynchronization therapy are potentially important prognostic indicators for post-surgery survival and reverse remodeling. (J Am Coll Cardiol Basic Trans Science 2016;1:193–202) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

METHODS

STUDY DESIGN. From September 2006 to August 2012, 50 consecutive patients with NICSMR who were scheduled for mitral surgery at the Hayama Heart Center, Kanagawa, Japan, were included in this observational study, which was approved by the local ethics committee. NICSMR stands for nonischemic, chronic, severe secondary mitral regurgitation. The term nonischemic in this study refers to idiopathic cardiomyopathy, as defined by the World Health Organization/International Society and Federation of Cardiology Task Force (14,15). All patients included were in an advanced symptomatic state (New York
Heart Association functional class III or IV), had already received the maximum GDMT for more than 6 months, had no prior surgical history, and provided written informed consent before inclusion in the study. The study flow chart and group categorization are shown in Figure 1. On the basis of the pre-operative baseline LV-Tor profile and QRS width (<120 or ≥120 ms), we divided the 50 patients into 3 groups: the Preserved, Lost, and WideQRS/CRT groups. The WideQRS/CRT group was subdivided into the PrevCRT (patients who received CRT before the mitral surgery) and PlusCRT (patients who were given CRT at the time of the mitral surgery) groups. All patients in the WideQRS/CRT group received CRT after the mitral surgery. We followed the clinical/survival status and echocardiographic variables of the 50 patients for at least 2 years after the mitral surgery.

**SURGICAL PROCEDURES.** Surgical correction of MR was performed with preservation of the subvalvular apparatus, which acts as a modulator of contractility and LV-Tor (16). Mitral valve (MV) repair was performed with annuloplasty (Carpentier-Edwards Physio or Physio II Annuloplasty Ring [Edwards Lifesciences, Irvine, California]; median ring size: 28 mm) with or without second chordal cutting and/or adding artificial chordae tendineae. According to the U.S. guidelines (2), MV repair was preferred over MV replacement if possible; replacement was performed in 9 patients (18%) on the basis of the surgeons’ intraoperative preference, and tricuspid surgery (annuloplasty with or without edge-to-edge repair) was performed in 29 patients (58%) who also had severe functional tricuspid regurgitation or tricuspid annulus dilation. For patients in the PlusCRT subgroup, an epicardial LV lead was placed intraoperatively and optimal CRT was performed immediately after the surgery.

**ECHOCARDIOGRAPHIC ANALYSIS.** All 2-dimensional (2D) echocardiographic measurements (including MR quantification according to the proximal isovelocity surface area method with angle correction) followed the recommendations of the American Society of Echocardiography and American Heart Association/American College of Cardiology (2,17). Conventional 2D, Doppler, and speckle tracking echocardiography (STE) were performed using commercially available equipment and analyzed on a workstation (Vivid7 or E9 with an M4S or M5S [1.5 to 4.3 MHz and 2.2 to 5.0 MHz] transducer and EchoPAC, GE Healthcare, Horten, Norway) as previously reported (12,18–20). LV contractility/elastance was determined with the end-systolic wall stress and volume ratio (ESWS/ESVI) (21–24).

**Definitions of “preserved” and “lost” LV torsion.** Using the systolic torsional profiles analyzed by 2D-STE, we

---

**FIGURE 1** Study Flow Chart and Group Categorization

- "NICSMR" patients scheduled elective mitral surgery (n=52)
  - Exclude; Inadequate echo images (n=2)
  - 50 pts were included in the study
  - QRS; width=120ms and LBBB morphology

- No (n=32)
  - Systolic LV torsional profile
  - Preserved-group (n=23)
  - Lost-group (n=9)
  - Mitral surgery
  - Follow-up ≥ 2 years
  - Survivors (n=31)
  - Non-Survivors (n=19)

- Yes (n=18)
  - [previously CRT implemented (prevCRT, n=6)]
  - WideQRS/CRT-group (n=18)
  - Mitral surgery
    - [+ CRT-implant (n=9)/ Upgrade (n=3)
      (plusCRT, n=12)]
  - All 18 had CRT

CRT = cardiac resynchronization therapy; echo = echocardiography; LBBB = left bundle branch block; LV = left ventricular; NICSMR = nonischemic chronic severe mitral regurgitation; pts = patients; Upgrade = upgrading to cardiac resynchronization therapy from a right ventricular pace/implantable cardioverter-defibrillator.
FIGURE 2 Averaged LV Rotation/Torsion Profile in the Preserved and Lost Groups

The LV rotation/torsion profile curves were averaged across all patients in each group. Blue, light green, and dark green indicate apical, mid-, and basal rotation, respectively. Purple indicates LV torsion. Time 0/100 indicates time of onset of QRS/AC. AC = aortic valve closed; AO = aortic valve open; LV = left ventricular.

FIGURE 3 Post-Operative Reverse Remodeling

The LV volume (A) and EF (B) were calculated with the area-length method. 1 week, 1 month, 6 months, 1 year, and 2 years indicate 1 week, 1 month, 6 months, 1 year, and 2 years after mitral surgery, respectively. The dotted line in the graphs indicates the number of remaining survivors was less than one-half of the initial number of patients (i.e., more than one-half died at that time). *Significantly different from baseline (Pre). #Significantly different from the prior study. D/L (C) = ratio of left ventricular diameter and length; EF = ejection fraction; ESWS/ESVI (D) = end-systolic wall-stress per indexed end-systolic volume (mm Hg/ml/m²); Mass (D) = indexed LV mass (g/m²); MR = mitral regurgitation; Pre = pre-operative baseline data.
divided narrow QRS patients into 2 groups: the Preserved and Lost (LV-Tor) groups. Preserved was defined as a preserved normal systolic torsional profile and positive net torsion (i.e., apical to basal rotation) through the systole following reverse torsion in the very early phase. Positive rotation or torsion was indicated by a counterclockwise direction when the LV was viewed from the apex. In most cases, this condition was the result of positive apical and negative basal rotation. Lost was defined as a loss of the normal systolic torsional profile, which was typically due to large negative apical rotation and small basal negative rotation. As a result, the LV-Tor typically due to large negative apical rotation and negative basal rotation.

**RESULTS**

The study was terminated in September 2014. We followed up with 42 patients (84%) at the Hayama Heart Center; the other patients’ data were provided by their primary attending physicians. The median follow-up term was 2.5 years (interquartile range: 0.9 to 4.5 years).

**PRE-OPERATIVE VARIABLES.** The baseline pre-operative variables of the entire cohort and the 2-year survivors/nonsurvivors after mitral surgery are shown in Table 1.

Pre-operative clinical status did not differ between post-operative survivors and nonsurvivors except when CRT had previously been used. The Society of Thoracic Surgeons scores among the Preserved, Lost, and WideQRS/CRT groups were also similar.

**STATISTICAL ANALYSIS.** The normality of the variables was assessed with the Kolmogorov-Smirnov test. Continuous variables are expressed as the mean ± SD if normally distributed or by the median (interquartile range) for variables with a skewed distribution. On the basis of the normality of the variables, the parametric or the nonparametric test was chosen as appropriate. Categorical variables are expressed as counts and percentages. The error bars in the LV torsional profiles and Figure 3 are shown as the mean ± SE. Comparisons between survivors and nonsurvivors were made using the Student t test or the Mann-Whitney U test. Categorical variables were analyzed using the chi-square test or Fisher exact test (when the expected cell frequency was <5). The categorical variables were analyzed with residual analysis to identify the category responsible for a chi-square statistic. Multiple comparisons were made among the 3 groups using analysis of variance or the Kruskal-Wallis test with Sheffe’s post-hoc analysis. Kaplan-Meier curves were constructed to show patients’ survival after the mitral surgery over time. The index date was the date of the surgery. The primary endpoints were analyzed until death (all causes), the implantation of VAD, or the study termination date. Survival among groups was compared using the log-rank test. Changes in variables from baseline to follow-up were analyzed using paired t tests or Wilcoxon matched-pairs analysis.

Statistical analysis was performed with the Statistical Package for Windows (Excel Statistics 2012, Social Survey Research Information Co., Ltd., Tokyo, Japan) and R software version 3.0.3 (R Foundation for Statistical Computing, Vienna, Austria). A 2-tailed p value <0.05 was considered significant.

**TABLE 1 Pre-Operative Variables**

|                     | Whole Cohort (n = 50) | 2 Years After Mitral Surgery | p Value |
|---------------------|-----------------------|------------------------------|---------|
| **Clinical indexes**|                       |                              |         |
| Age, yrs            | 62 ± 11               | 63 ± 10                      | 62 ± 12 | 0.81  |
| Female              | 15 (30)               | 11 (35)                      | 4 (21)  | 0.35  |
| Body surface area, m²| 1.59 ± 0.20           | 1.63 (1.47-1.77)             | 1.57 (1.43-1.66) | 0.30  |
| Body mass index, kg/m²| 21 ± 3              | 21 ± 3                       | 20 ± 3  | 0.16  |
| Atrial fibrillation/flutter | 13 (26)            | 10 (32)                      | 3 (16)  | 0.32  |
| QRS width, ms       | 116 (98-136)          | 103 (96-135)                 | 118 (100-152) | 0.33  |
| Previous CRT        | 6 (12)                | 1 (3)                        | 5 (26)  | 0.024 |
| NYHA functional class| 3.6 ± 0.5             | 3.5 ± 0.5                    | 3.7 ± 0.5 | 0.39  |
| III                 | 20 (40)               | 17 (33)                      | 13 (68) | 0.39  |
| IV                  | 30 (60)               | 14 (45)                      | 6 (32)  | 0.23  |
| STS score           | 1.20 (0.95-2.14)      | 1.15 (0.91-1.82)             | 1.24 (0.99-3.01) | 0.23  |
| **Echocardiographic indexes** |                   |                              |         |
| LV end-diastolic dimension/BSA, cm²/m² | 4.6 ± 0.6           | 4.5 (4.1-5.0)                | 4.8 (4.3-4.9) | 0.07  |
| LV end-diastolic volume/BSA, ml/m² | 132 (111-145)      | 124 (107-140)                | 142 (129-165) | 0.005 |
| Area-length         | 170 ± 46              | 162 ± 47                     | 181 ± 43 | 0.17  |
| LV ejection fraction, %| 27 ± 8              | 27 ± 9                      | 26 ± 6  | 0.80  |
| Area-length         | 24 (20-36)            | 27 (20-37)                   | 23 (20-26) | 0.18  |
| LV shape, diameter/length | 0.77 ± 0.07         | 0.76 ± 0.07                  | 0.79 ± 0.07 | 0.12  |
| LV mass/BSA, g/m²   | 180 ± 45              | 174 ± 44                     | 189 ± 46 | 0.25  |
| LV torsion, °       | 4.6 ± 6.0             | 6.1 ± 4.7                    | 2.0 ± 7.3 | 0.018 |
| Left atrial volume/BSA, ml/m² | 80 (55-131)     | 74 (54-105)                  | 99 (75-136) | 0.23  |
| MR volume/BSA, ml/m²| 31 ± 8               | 31 ± 8                       | 31 ± 7  | 0.90  |
| Effective regurgitant orifice area of the MR, cm² | 0.41 (0.31-0.50) | 0.35 (0.31-0.49)          | 0.46 (0.34-0.54) | 0.09  |

Values are mean ± SD, n (%), or median (interquartile range). Society of Thoracic Surgeons score was calculated on version 2.81. Values in bold indicate a significant p value (p < 0.05).

BSA = body surface area; CRT = cardiac resynchronization therapy; LV = left ventricular; MR = mitral regurgitation; NYHA = New York Heart Association.
In general, a difference between the study groups could not be found in the pre-operative variables (Supplemental Table 2).

Baseline LV size, shape, and mass tended to be larger and more spherical in nonsurvivors; however, there was no statistical difference except in the LV volume estimated by the biplane disk summation. The LV ejection fraction and MR severity were virtually identical among the groups; the LV torsion, however, was higher in survivors.

**POST-OPERATIVE SURVIVAL.** During the study period, there was no operative mortality; 19 patients reached the primary endpoint: 12 died of congestive heart failure, 1 received VAD implantation, 4 died suddenly, and 2 died of noncardiac causes (1 from pneumonia and 1 from infectious spondylitis). These 2 noncardiac deaths occurred in the Preserved group.

The Central illustration shows the LV torsional profiles and Kaplan-Meier curves for the endpoint in the 3 categorized groups (panel A) and in the subgroups of the WideQRS/CRT group (panel B). In panel A, the end-systolic LV torsion was significantly higher in the Preserved group (8.2 ± 3.6°) than in the Lost (−1.4 ± 5.0°) and WideQRS/CRT (3.2 ± 6.1°) groups, but there was no significant difference between the Lost and WideQRS/CRT groups. The log-rank test indicated a significant difference in the 2-year survival among the 3 groups (87%, 22%, and 50%; log-rank p < 0.0002). There was also a significant difference between the Preserved and WideQRS/CRT groups (p < 0.007) but not between the WideQRS/CRT and Lost groups (p = 0.067, but statistical power 0.39).

In panel B, although the LV torsional profile was not significantly different between the subgroups (end-systolic torsion: 2.7 ± 4.5° in PlusCRT and 4.5 ± 4.5° in PrevCRT; p = 0.45), the PrevCRT group showed significantly worse 2-year survival than the PlusCRT group (17% vs. 67%; log-rank p < 0.006).

Congestive heart failure hospitalization was very frequent in patients in the Lost group (67%) but relatively infrequent in the Preserved group (9%). Moderate or higher MR recurrence after mitral repair was observed in 2 patients in the Preserved group and...
1 patient each in the Lost and WideQRS/CRT groups during follow-up; this was treated medically in all cases.

**POST-OPERATIVE REVERSE REMODELING.** Figure 3 shows the degree and course of the LV reverse remodeling in each of the 3 groups.

To better understand the reverse remodeling after mitral surgery, we also analyzed the comparative data of age- and sex-matched 18 normal subjects and 12 patients with primary MR.

**Figure 3A.** At 1 week and 1 month, decreased LV size as a result of volume unloading with mitral surgery was observed in all groups except for the Lost group. After 1 to 6 months, in the Preserved group, the LV end-diastolic volume (EDV) gradually decreased, whereas the LV end-systolic volume slowly and significantly decreased after 2 years compared with the baseline (19 ± 39% reduction from baseline; p = 0.027), but it remained high (112 ± 47 ml/m²) to 89 ± 48 ml/m²). The LVEDV in the primary MR group returned to a normal level sooner than in the other groups. No significant LV volume reduction was observed in the WideQRS/CRT or Lost groups after 2 years. Even the PlusCRT subgroup of the WideQRS/CRT group did not manifest significant reverse remodeling; the end-systolic volume/body surface area values were baseline: 141 ± 51 ml/m²; 1 year: 152 ± 41 ml/m² (p = 0.09); and 2 years: 136 ± 36 ml/m² (p = 0.32 vs. baseline).

**Figure 3B.** LV function tended to show a mild transient decrease from 1 week to 6 months after surgery in all groups, and thereafter returned to a normal level in the primary MR group and to the baseline level in the Preserved group at 6 months. The Preserved group showed delayed and insignificant improvement over the course of 2 years, whereas the other groups did not.

**Figure 3C.** The LV shape gradually became more elliptical toward normal only in the Preserved group (but still spherical at 2 years), whereas the shape rapidly normalized in primary MR.

**Figure 3D.** Transient LV mass increment at 1 week (suggesting the effect of cardioplegia) was observed in all groups except for the Lost group. The LV mass returned to the baseline level at 1 month and was stable thereafter, except in the primary MR group. The primary MR group continued to exhibit regression of the LV mass to the normal level over 2 years, whereas the Preserved group did not show similar regression.

**Figure 3E.** The LV contractility/elastance of the primary MR group was normalized over a period of 2 years, but the NICSMR groups did not increase more than the baseline.

It should be mentioned that most trends of reverse remodeling in the WideQRS/CRT group were not found to be dissimilar to those in PrevCRT and/or PlusCRT patients. One reason for this finding is that most patients in the PrevCRT subgroup died within 1 year.

**DISCUSSION**

The main findings of the current study are as follows:

1. For patients with NICSMR and a narrow QRS width, preserved LV-Tor may be a better predictor of post-mitral surgery survival; conversely, lost LV-Tor may imply a poor post-surgical outcome. Importantly, pre-operative LV size, EF, and geometric shape were not significantly different between 2-year survivors and nonsurvivors in our cohort.

2. The post-surgical survival results were intermediate in patients with a wide (LBBB pattern) QRS. This group was divided into 2 subgroups for discussion because patients who had previously undergone CRT had significantly poorer survival, and those with newly performed CRT at the time of surgery had relatively better survival after mitral surgery, although the 2 subgroups had a similar LV-Tor.

3. Therefore, lost LV-Tor and previously administered CRT appeared to be markers of poor survival after mitral surgery in patients with NICSMR.

4. Reverse remodeling was observed only in the preserved LV-Tor group. Hence, lost LV-Tor and wide QRS (even in the PlusCRT subgroup) were markers of no reverse remodeling viability.

In short, as a clinical scenario, patients with NICSMR who have lost LV-Tor and a narrow QRS width or previous CRT implementation appeared to benefit less from mitral surgery; however, for patients with preserved LV-Tor and a narrow QRS, mitral surgery seemed to be an acceptable option. Thus, the assessment of LV-Tor may be useful for the prediction of post-mitral surgery outcomes in patients with a narrow QRS but not in those with a wide QRS, including patients with previous CRT implementation.

Hereafter, we discuss the pathophysiological rationale and clinical relevance of the current study.

**LV-TOR AND REVERSE REMODELING: RECOVERY, REMISSION, OR PLASTIC.** Although patients in the Preserved group showed a significant reverse “chamber” remodeling after MR elimination, the LV mass did not regress (keeping the initial mass volume) over 2 years; consequently, it re-remodeled toward concentric LV geometry. This re-remodeling appeared to lead to a decrease in wall stress without an increase in ESWS/ESVI during the 2 years of
follow-up. This finding was in contrast to the reverse remodeling course of primary MR, which showed a decrease in both chamber and mass and could truly be called “recovery” (improvement of the myocytes’ contractility). The Preserved group, therefore, appeared to be in “remission” (maintaining initial contractility) rather than recovery (25). To normalize the LV performance, with weak and compromised myocardium/myocytes this “re-remodeling” would be required. Thus, patients with preserved torsion would receive minimal (survival) benefit from volume unloading treatment.

In addition, the “plastic region” (25) might be characterized in the Lost group by no significant LV-Tor (hence, no chamber elliptization during systole) (Supplemental Table 3), poor post-surgical survival, and no reverse remodeling, in which the LV myocardium was irreversibly damaged and did not have the ability to respond to the volume-unloading treatment. The LV in the Lost group also appeared to be entirely pre-load dependent; it did not decrease in LVEDV after surgery (instead exhibiting re-dilation). The LV in the Lost group may have sustained irreversible myocellular damage in the plastic or “creep” region (irreversible “slippage” between myofibrils [26]) and did not achieve “remission” after mitral surgery. Thus, the lost LV-Tor profile might be a sign of requiring a ventricular assistance device.

Together, our results suggest the hypothesis that LV torsion may indicate the contractility/elastance (which enables reverse remodeling) of the LV compromised myocardium in NICSMR patients. LV-Tor was modestly but significantly correlated with ESWS/ESVI in our cohort ($r^2 = 0.17$; $p = 0.003$).

**CRT in NICSMR. Pathophysiology.** It has been suggested that LV torsional mechanics require a normal synchrony (normal and rapid LV activation sequence) and that LV rotation mechanics may not be an essential component of LV function in cases of LV dyssynchrony and epicardially paced resynchronization (13). In other words, LV in LBBB and CRT contracts without torsional mechanics, which is a physiological advantage on the basis of the architecture. This contraction may be why the WideQRS/CRT group showed unusual LV torsional profiles, which required the creation of another group.

The mechanical discoordination indexes CURE (circumferential uniformity ratio estimate) (27) and ISF (internal stretch fraction) (28), calculated by the numerical data derived from 2D-STE, showed borderline discoordination values in both the PrevCRT and PlusCRT subgroups (Supplemental Table 4). Thus, the PrevCRT subgroup maintained some degree of discoordination, whereas the PlusCRT group did not exhibit severe discoordination. This difference may explain why volume unloading (mitral surgery) and resynchronization would not be effective for promoting reverse remodeling in both subgroups. Additionally, favored reverse remodeling might be prevented by surgical factors such as systemic inflammatory response or myocardial oxidative stress/free radical injury with cardiopulmonary bypass, cardioplegia, and complete cardiac arrest. Hence, implementation of CRT before mitral surgery on the basis of appropriate indications would be needed, as suggested in the guidelines.

**Correction of Unimproved MR After CRT in NICSMR.** Although the effect of CRT on secondary MR was clear, MR persists in 30% to 40% of CRT patients (29–31) in the real world. The natural history of CRT nonresponders (nonfunctional MR improvers) is poor, with a reported 2-year mortality of 50% (29,30) and 3-year mortality up to 70% (31). In the present study, surgical correction of unimproved MR after CRT in NICSMR was unsuccessful. A recent report on the MitraClip (Abbott Vascular, Santa Clara, California), however, has demonstrated excellent results in such patients and “it emphasized the need to stratify early after CRT those patients who may either develop FMR or in whom FMR is unlikely to change (decrease) as well as need to consider additional therapeutic options such as (mitral) surgery or MitraClip treatment” (32).

**Study Limitations and Future Directions.** We should address several limitations of this observational study, which was conducted at a single center. Although consecutive patients were selected from a real-world clinic, the patient population was small and the follow-up term was short. A larger number of WideQRS/CRT group patients, specifically, should be included in the future to obtain more robust conclusions.

The mean effective regurgitant orifice area/regurgitant volume/regurgitant fraction was 0.41 cm²/48 ml/60% in the entire cohort. Because the current Western guidelines (2,23) indicate a value $>0.2$ cm²$>/>30$ ml$>/>50%$ as severe, the symptoms of many patients observed in this study might have been too severe (or too late) at the time of referral to surgery. Unexpectedly, LV size, EF, and shape were not post-operative discriminators in this study. No assumption method using robust high-resolution 3-dimensional imaging (echocardiography or CMR) modalities can accurately assess the MR and LV volume (34–36).

Although it was beyond the scope of the current study, it is of note that nonsurvivors in our
cohort tended to have a larger right ventricle (possibly related to more required tricuspid surgery and higher levels of brain natriuretic peptide) (Supplemental Table 5). Right ventricular size was weakly inversely related to LV-Tor ($r^2 = 0.10; p = 0.026$). A multivariate Cox analysis in an appropriately sized randomized study might be able to determine the significance and independence of those indexes with sufficient statistical power. In the current study, the small sample precluded the ability to adjust for potential confounding factors when analyzing survival.

We did not include a medically treated control group. A randomized prospective trial of mitral surgery and GDMT in far-advanced LV dysfunction and heart failure has not been explored to date. It may be appropriate to determine the best clinical approach for NICSMR patients with the results of an analysis of quality-adjusted life-years and incremental cost-effectiveness in such trials. VAD as a destination therapy generally leads to 70% survival at 2 years (37), which may serve as a measure of survival success for other resources. The ongoing COAPT study (NCT01626079) involving patients with NICS MR with and without CRT will shed light on this issue. Finally, to treat primary myopathy, regenerative therapy to attain myocardial “recovery” would potentially facilitate therapeutic responses in NICS MR patients.

CONCLUSIONS

In patients with NICS MR, the LV torsional profile assessed with 2D-STE discriminated post-mitral surgery outcomes in patients with a narrow QRS but not in those with a wide QRS, and previously implemented CRT appeared to be a marker of poor post-surgical survival.

The National Institutes of Health Fact Sheet (38) states that among adults, the 5-year relative survival rate for all cancers combined is now approximately 68%, whereas it was 50% in our entire cohort. Determining the safest and most effective management for NICS MR patients is the goal. The findings of this study may help to resolve this clinical dilemma and identify appropriate candidates for mitral surgery in patients with NICS MR.

REFERENCES

1. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). J Am Coll Cardiol 2008;52:e1.

2. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:e139-282.

3. Di Salvo TG, Acker MA, Dec GW, Byrne JG. Mitral valve surgery in advanced heart failure. J Am Coll Cardiol 2010;55:271-82.

4. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 2005;45:381-7.

5. Acker MA, Jessup M, Bolling SF, et al. Mitral valve repair in heart failure: five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial. J Thorac Cardiovasc Surg 2011;142:S69-74, 574-1.

6. De Bonis M, Lapenna E, La Canna G, et al. Mitral valve repair for functional mitral regurgitation in end-stage dilated cardiomyopathy: role of the “edge-to-edge” technique. Circulation 2005;112:1402-8.

7. Geidel S, Lass M, Krause K, et al. Early and late results of restrictive mitral valve annuloplasty in 121 patients with cardiomyopathy and chronic mitral regurgitation. Thorac Cardiovasc Surg 2008;56:262-8.

8. Calafiore AM, Galina S, Di Mauro M, et al. Mitral valve procedure in dilated cardiomyopathy: repair or replacement? Ann Thorac Surg 2001;71:1146-52, discussion 1152-3.

9. Gummert JF, Rahmel A, Bucerius J, et al. Mitral valve repair in patients with end stage cardiomyopathy: who benefits? Eur J Cardiothorac Surg 2003;23:1017-22. discussion 1022.

10. Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Heart Rhythm Society, American Heart Association, American Society of...
Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2013;61:1318-68.

11. Dong SJ, Hees PS, Huang WM, Buffer SA Jr., Weiss JL, Shapiro EP. Independent effects of preload, afterload, and contractility on left ventricular torsion. Am J Physiol 1999;277:H1053-60.

12. Notomi Y, Popovic ZB, Yamada H, et al. Ventricular untwisting: a temporal link between left ventricular relaxation and suction. Am J Physiol 1999;277:H1053.

13. Ashikaga H, Leclairc Q, Wang J, Kass DA, McVeigh ER. Hemodynamic improvement in cardiac resynchronization does not require improvement in left ventricular rotation mechanics: three-dimensional tagged MRI analysis. Circ Cardiovasc Imaging 2010;3:456-63.

14. Report of the WHO/ISFC Task Force on the Definition and Classification of Cardiomyopathies. Br Heart J 1980;44:672-3.

15. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996;93:841-2.

16. De Anda A Jr., Komeda M, Nikolic SD, Daughters GT 2nd, Ingels NB, Miller DC. Left ventricular function, twist, and recoil after mitral valve replacement. Circulation 1995;92: II458-66.

17. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.e14.

18. Notomi Y, Lysyansky P, Setser RM, et al. Measurement of ventricular torsion by two-dimensional ultrasonic speckle tracking imaging. J Am Coll Cardiol 2005;45:2034-41.

19. Notomi Y, Martin-Miklovic MG, Oryszak SJ, et al. Enhanced ventricular untwisting during exercise: a mechanistic manifestation of elastic recoil described by Doppler tissue imaging. Circulation 2006;113:2524-31.

20. Notomi Y, Sinath G, Shiota T, et al. Maturational and adaptive modulation of left ventricular torsional biomechanics: Doppler tissue imaging observation from childhood to adulthood. Circulation 2006;113:2534-41.

21. Mirsky I. Left ventricular stress in the intact human heart. Biophys J 1969;9:189-208.

22. Kelly RP, Ting CT, Yang TM, et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation 1992;86:513-21.

23. Rozich JD, Carabello BA, Usher BW, Kratz JM, Bell AE, Zile MR. Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance. Circulation 1992;86:1718-26.

24. Carabello BA, Nolan SP, McGuire LB. Assessment of preoperative left ventricular function in patients with mitral regurgitation: value of the end-systolic wall stress-end-systolic volume ratio. Circulation 1981;64:1212-7.

25. Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol 2012;60: 2465-72.

26. Ross J Jr., Sonnenblick EH, Taylor RR, Spotnitz HM, Covelli JW. Diastolic geometry and sarcomere lengths in the chronically dilated canine left ventricle. Circ Res 1971;28:49-61.

27. Helm RH, Leclairc C, Faris OP, et al. Cardiac dyssynchrony analysis using circumferential versus longitudinal strain: implications for assessing cardiac resynchronization. Circulation 2005;111:2760-7.

28. Kinn B, Jansen A, Bracke F, van Gelder B, Arts T, Prinzen FW. Mechanical discoordination rather than dyssynchrony predicts reverse remodeling upon cardiac resynchronization. Am J Physiol Heart Circ Physiol 2008;295:H640-6.

29. van Bommel RJ, Marsan NA, Delgado V, et al. Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk. Circulation 2011;124:912-9.

30. Verhaert D, Popovic ZB, De S, et al. Impact of mitral regurgitation on reverse remodeling and outcome in patients undergoing cardiac resynchronization therapy. Circ Cardiovasc Imaging 2012;5:21-6.

31. Ypenburg C, van Bommel RJ, Borleffs CJ, et al. Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. J Am Coll Cardiol 2009;53:483-90.

32. Auricchio A, Schilling W, Meyer S, et al. Correction of mitral regurgitation in nonresponders to cardiac resynchronization therapy by MitraClip improves symptoms and promotes reverse remodeling. J Am Coll Cardiol 2011;58:2183-9.

33. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012;42: S1-44.

34. Uretsky S, Gillam L, Lang R, et al. Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial. J Am Coll Cardiol 2015;65:1078-88.

35. Aggar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol 2015;65:1231-48.

36. Grayburn PA, Carabello B, Hung J, et al. Defining “severe” secondary mitral regurgitation: emphasizing an integrated approach. J Am Coll Cardiol 2014;64:2792-801.

37. Long EF, Swain GW, Mangi AA. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Circ Heart Fail 2014;7:470-8.

38. U.S. Department of Health & Human Services. NIH Fact Sheets: Cancer. Available at: https://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=75. Accessed May 2016.

**KEY WORDS** cardiac resynchronization therapy, LV reverse remodeling, LV torsion, mitral surgery, nonischemic chronic secondary mitral regurgitation

**APPENDIX** For supplemental tables, please see the online version of this article.